401 results on '"Enomoto, Yutaka"'
Search Results
152. Idiopathic retroperitoneal fibrosis, inflammatory aortic aneurysm, and inflammatory pericarditis--Retrospective analysis of 11 case histories.
- Author
-
Sakamot, Aiko, Nagai, Ryozo, Saito, Kan, Imai, Yasushi, Takahashi, Masao, Hosoya, Yumiko, Takeda, Norifumi, Hirano, Kenji, Koike, Kazuhiko, Enomoto, Yutaka, Kume, Haruki, Homma, Yukio, Maeda, Daichi, Yamada, Hideomi, Fukayama, Masashi, Hirata, Yasunobu, and Ishizaka, Nobukazu
- Subjects
RETROPERITONEAL fibrosis ,AORTIC aneurysms ,INFLAMMATION ,RETROSPECTIVE studies ,CELLULAR immunity ,CLINICAL trials ,IMMUNOGLOBULIN G - Abstract
Retroperitoneal fibrosis, inflammatory aortic aneurysm, and pericardial and medi-astinal fibrosis are characterized by infiltration of immuno-inflammatory cells and deposition of thickened fibrous tissues. Several recent studies suggested that an immunoglobulin (lgG4)-related immunological mechanism may play a role in these diseases. By searching the clinical database of patients admitted to our department between 2000 and 2010, we summarized the clinical data of 11 patients who were diagnosed to have these disorders. The diagnoses were idiopathic retroperitoneal fibrosis (8 cases), mediastinal and/or pericardial fibrosis (4 cases), inflammatory abdominal aneurysm (2 cases), and inflammatory coronary periarteritis (1 case). Hypertension, diabetes, and dyslipidemia were found in 45%, 36%, and 55%, respectively, in these patients, and they were all either current or former smokers. Two patients with peri-cardial involvement showed a rushed clinical course, resulting in in-hospital death. Serum levels of IgG were elevated in 67%, and soluble interleukin-2 receptor was elevated in 75%, when mea-sured. Immunohistochemical analysis showed marked infiltration of lgG4-positive plasma cells in the pericardium in patients who died of constrictive pericarditis. Our data support the notion that immune-inflammatory mechanism, which might be lgG4-related sometimes, may play a role in idiopathic retroperitoneal fibrosis, inflammatory aortic aneurysm, and mediastinal/pericardial fibrosis, although clinical course may differ substantially. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
153. Infection of Tobacco Plant with Cucumber Mosaic Virus through Roots
- Author
-
TOMARU, Keiichi, primary, MAEDA, Susumu, additional, and ENOMOTO, Yutaka, additional
- Published
- 1971
- Full Text
- View/download PDF
154. C-Terminal-Truncating ASXL1Mutations Induce MDS Via Inhibition Of PRC2
- Author
-
Inoue, Daichi, Kitaura, Jiro, Togami, Katsuhiro, Nishimura, Koutarou, Enomoto, Yutaka, Uchida, Tomoyuki, Kagiyama, Yuki, Kawabata, Kimihito Cojin, Nakahara, Fumio, Oki, Toshihiko, Harada, Hironori, Ochiya, Takahiro, Aburatani, Hiroyuki, Kimura, Hiroshi, Thol, Felicitas, Heuser, Michael, Levine, Ross L., Abdel-Wahab, Omar, and Kitamura, Toshio
- Abstract
Recurrent mutations of ASXL1(Additional sex combs-like1) are found in various hematological malignancies including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, and acute myeloid leukemia (AML) with myelodysplasia-related changes. Additionally, ASXL1mutations are linked with adverse survival in a variety of myeloid malignancies. A previous study demonstrated that loss of ASXL1 in mice promotes myeloid transformation by impairing polycomb repressive complex 2 (PRC2)-mediated gene repression at a number of critical loci and leads to myeloid transformation. However, most ASXL1mutations are heterozygous and located in the 5' region of the last exon, indicating a dominant-negative or gain-of-function feature of a truncated ASXL1 protein. Therefore, we investigated if the C-terminal truncated form of ASXL1 (ASXL1-MT) contributes to the development of myeloid malignancies. To this end, we examined the effects of ASXL1-MT using in vitroand in vivoexperiments.
- Published
- 2013
- Full Text
- View/download PDF
155. Prognostic significance of the albumin-to-globulin ratio for advanced urothelial carcinoma treated with pembrolizumab: a multicenter retrospective study.
- Author
-
Taguchi, Satoru, Kawai, Taketo, Nakagawa, Tohru, Nakamura, Yu, Kamei, Jun, Obinata, Daisuke, Yamaguchi, Kenya, Kaneko, Tomoyuki, Kakutani, Shigenori, Tokunaga, Mayuko, Uemura, Yukari, Sato, Yusuke, Fujimura, Tetsuya, Fukuhara, Hiroshi, Enomoto, Yutaka, Nishimatsu, Hiroaki, Takahashi, Satoru, and Kume, Haruki
- Subjects
- *
TRANSITIONAL cell carcinoma , *GLOBULINS , *ALBUMINS , *PEMBROLIZUMAB , *BIOMARKERS - Abstract
Although the albumin-to-globulin ratio (AGR) is a promising biomarker, no study has investigated its prognostic significance for advanced urothelial carcinoma (UC). This study conformed to the REporting recommendations for tumor MARKer prognostic studies (REMARK) criteria. We retrospectively reviewed 176 patients with advanced UC treated with pembrolizumab between 2018 and 2020. We evaluated the associations between pretreatment clinicopathological variables, including the AGR and performance status (PS), with progression-free survival, cancer-specific survival, and overall survival. The Cox proportional hazards model was used for univariate and multivariable analyses. The AGR was dichotomized as < 0.95 and ≥ 0.95 based on receiver operating characteristic curve analysis. After excluding 26 cases with missing data from the total of 176 cases, 109 (73%) patients experienced disease progression, 75 (50%) died from UC, and 6 (4%) died of other causes (median survival = 12 months). Multivariate analyses identified PS ≥ 2 and pretreatment AGR < 0.95 as independent poor prognostic factors for all endpoints. Furthermore, a prognostic risk model incorporating these two variables achieved a relatively high concordance index for all endpoints. This is the first report to evaluate the significance of AGR in advanced UC. Pretreatment AGR < 0.95 may serve as a prognostic marker for advanced UC treated with pembrolizumab. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
156. Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan.
- Author
-
Ikeda, Atsushi, Kojima, Takahiro, Kawai, Koji, Hinotsu, Shiro, Keino, Naoto, Shiga, Kenichiro, Miyake, Hideaki, Miyata, Yasuyoshi, Enomoto, Yutaka, Shimizu, Fumitaka, Anai, Satoshi, Matsuyama, Hideyasu, Suzuki, Chieko, Kanimoto, Yusuke, Shigeta, Keisuke, Naito, Seiji, Akaza, Hideyuki, and Nishiyama, Hiroyuki
- Subjects
- *
FLUORESCENCE in situ hybridization , *CANCER relapse , *BLADDER cancer , *LONGITUDINAL method , *INTEREST rates - Abstract
Background: A previous comparative study in Japan has demonstrated that the two consecutive UroVysion tests are useful tools to detect the presence of bladder cancer during follow-up after transurethral resection, but they also presented their high rates of false-positive results. Here, we aimed to evaluate the relationship between the UroVysion tests and subsequent intravesical recurrence. Methods: In the previous study, patients without bladder cancer during the first analysis showed the same examination set repeated 3 months later as the second analysis. In this follow-up study, 326 patients showed negative findings confirmed on cystoscopy during the second UroVysion test. Recurrence-free survival was assessed using a median follow-up of 27 months. Results: In the two consecutive UroVysion tests, 214 patients (65.6%) showed negative UroVysion results in both tests, whereas 91 presented a positive result on either tests and 21 patients presented positive results in both tests. During the follow-up, 40 patients (12.3%) had an intravesical recurrence with non-muscle-invasive bladder cancer. The recurrence rates in patients with negative results in both tests, those with one positive result in either tests, and those with positive results in both tests were 8.4%, 16.5%, and 33.3%, respectively. The multivariate analysis indicated that the history of bladder cancer and the consecutive UroVysion test pattern were independent risk factors for recurrence. Conclusions: Our data confirmed the effectiveness of two consecutive UroVysion tests in predicting intravesical recurrence after TURBT. Further prospective studies would help determine an appropriate interval for cystoscopy follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
157. Clinical evaluation of two consecutive UroVysion fluorescence in situ hybridization tests to detect intravesical recurrence of bladder cancer: a prospective blinded comparative study in Japan.
- Author
-
Kojima, Takahiro, Nishiyama, Hiroyuki, Ozono, Seiichiro, Hinotsu, Shiro, Keino, Naoto, Yamaguchi, Akito, Sakai, Hideki, Enomoto, Yutaka, Horie, Shigeo, Fujimoto, Kiyohide, Matsuyama, Hideyasu, Okamura, Takehiko, Kanimoto, Yusuke, Oya, Mototsugu, Nonomura, Norio, Naito, Seiji, and Akaza, Hideyuki
- Subjects
- *
BLADDER cancer , *CANCER relapse , *FLUORESCENCE in situ hybridization , *TRANSURETHRAL prostatectomy - Abstract
Background: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT).Methods: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests.Results: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2-64.8%) sensitivity and 72.4% (68.3-76.8%). Urine cytology had 4.5% (0.0-10.7%) sensitivity and 99.8% (99.3-100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up.Conclusions: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
158. Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder.
- Author
-
Naito, Akihiro, Taguchi, Satoru, Nakagawa, Tohru, Matsumoto, Akihiko, Nagase, Yasushi, Tabata, Mariko, Miyakawa, Jimpei, Suzuki, Motofumi, Nishimatsu, Hiroaki, Enomoto, Yutaka, Takahashi, Shintaro, Okaneya, Toshikazu, Yamada, Daisuke, Tachikawa, Takamitsu, Minowada, Shigeru, Fujimura, Tetsuya, Fukuhara, Hiroshi, Kume, Haruki, and Homma, Yukio
- Subjects
- *
BLADDER cancer , *SMALL cell carcinoma , *BLOOD serum analysis , *ENOLASE , *BIOMARKERS , *PROGNOSIS - Abstract
Purpose: Small cell carcinoma of the urinary bladder (SCCB) is known for its aggressive clinical features and poor prognosis. No prognostic factor has been established so far. The aim of this study was to assess the significance of possible prognostic factors, including serum neuron-specific enolase (NSE), an established biomarker for small cell lung carcinoma. Methods: We retrospectively reviewed 31 patients with primary SCCB treated at our eight affiliate institutions between 2001 and 2014. The association of various clinicopathological factors at diagnosis, including the serum NSE value, with cancer-specific survival (CSS) was assessed. The log-rank test and Cox proportional hazards model were used for univariate and multivariate analyses, respectively. Results: Nineteen (61.3 %) died of SCCB during the follow-up, with a median survival time of 12.7 months. Prognostic factors were analyzed for the 25 patients after excluding six with missing data. Univariate analysis demonstrated that stage (extensive disease) and serum NSE ≥25 ng/ml were significantly associated with worse CSS. Multivariate analysis identified increased serum NSE value as a sole independent predictor of CSS (hazard ratio 18.52, p = 0.0022). Conclusions: Serum NSE value at diagnosis was an independent prognostic factor for primary SCCB and may serve as a useful biomarker in the management of SCCB. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
159. Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world.
- Author
-
Taguchi, Satoru, Nakagawa, Tohru, Uemura, Yukari, Matsumoto, Akihiko, Nagase, Yasushi, Kawai, Taketo, Tanaka, Yoshinori, Yoshida, Kanae, Yamamoto, Sachi, Enomoto, Yutaka, Nose, Yorito, Sato, Toshikazu, Ishikawa, Akira, Fujimura, Tetsuya, Fukuhara, Hiroshi, Kume, Haruki, and Homma, Yukio
- Subjects
- *
METASTASIS , *TRANSITIONAL cell carcinoma , *COHORT analysis , *PERFORMANCE evaluation , *FOLLOW-up studies (Medicine) , *MULTIVARIATE analysis - Abstract
Background: Several prognostic models predicting survival of patients with metastatic urothelial carcinoma (UC) have been developed; however, of them, the first model by Bajorin in 1999 is still the most representative and widely used, and validations of newer models are lacking. This study aimed to validate three major prognostic models for metastatic UC constructed based on clinical trials. Methods: We reviewed 200 patients with metastatic UC who received first-line chemotherapy at our five affiliate institutions between 2003 and 2011. Using this multi-institutional cohort, we validated the following models: the 'Bajorin model,' a model consisting of visceral metastasis and performance status; the 'Apolo model,' a nomogram including visceral metastasis, performance status, albumin and hemoglobin; and the 'Galsky model,' a nomogram including leukocyte count, number of sites of visceral metastases, site of primary tumor, performance status and lymph node metastasis. Harrell's c-index was calculated for each model. Cox proportional hazards regression model was used for multivariate analysis. Results: Among 200 patients, 171 (85.5 %) died during the follow-up, with a median survival of 12.0 months. Multivariate analysis demonstrated ECOG performance status, visceral metastasis and leukocyte count to be independent predictors of overall survival. C-index results (95 % confidence interval) were Bajorin: 0.86 (0.74-0.95); Apolo: 0.89 (0.78-0.98); and Galsky: 0.82 (0.69-0.93). Conclusions: All models were demonstrated to have high external validities in real-world patients, and of them, the 'Apolo model' achieved the highest c-index in the present population. Further studies with larger populations are needed for establishment of the next standard model. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
160. Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome.
- Author
-
Nakamura, Motonobu, Yamazaki, Osamu, Shirai, Ayumi, Horita, Shoko, Satoh, Nobuhiko, Suzuki, Masashi, Hamasaki, Yoshifumi, Noiri, Eisei, Kume, Haruki, Enomoto, Yutaka, Homma, Yukio, and Seki, George
- Subjects
- *
HYPERINSULINISM , *HYPERTENSION , *INSULIN , *FAT cells , *SODIUM bicarbonate , *METABOLIC syndrome - Abstract
Hyperinsulinemia can contribute to hypertension through effects on sodium transport. To test whether the stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in insulin resistance, we compared the effects of insulin on abdominal adipocytes and proximal tubules in rats and humans. Insulin markedly stimulated the sodium-bicarbonate cotransporter (NBCe1) activity in isolated proximal tubules through the phosphoinositide 3-kinase (PI3-K) pathway. Gene silencing in rats showed that while insulin receptor substrate (IRS)1 mediates the insulin effect on glucose uptake into adipocytes, IRS2 mediates the insulin effect on proximal tubule transport. The stimulatory effect of insulin on glucose uptake into adipocytes was severely reduced, but its stimulatory effect on NBCe1 activity was completely preserved in insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rats and patients with insulin resistance. Despite widespread reduction of IRS1 and IRS2 expression in insulin-sensitive tissues, IRS2 expression in the kidney cortex was exceptionally preserved in both OLETF rats and patients with insulin resistance. Unlike liver, acute insulin injection failed to change the expression levels of IRS2 and sterol regulatory element-binding protein 1 in rat kidney cortex, indicating that regulatory mechanisms of IRS2 expression are distinct in liver and kidney. Thus, preserved stimulation of proximal tubule transport through the insulin/IRS2/PI3-K pathway may play an important role in the pathogenesis of hypertension associated with metabolic syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
161. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
- Author
-
Inoue, Daichi, Kitaura, Jiro, Togami, Katsuhiro, Nishimura, Koutarou, Enomoto, Yutaka, Uchida, Tomoyuki, Kagiyama, Yuki, Kawabata, Kimihito Cojin, Nakahara, Fumio, Izawa, Kumi, Oki, Toshihiko, Maehara, Akie, Isobe, Masamichi, Tsuchiya, Akiho, Harada, Yuka, Harada, Hironori, Ochiya, Takahiro, Aburatani, Hiroyuki, Kimura, Hiroshi, and Thol, Felicitas
- Subjects
- *
ANIMAL experimentation , *BIOLOGICAL models , *CELL lines , *CELL receptors , *HEMATOPOIESIS , *METHYLATION , *MICE , *GENETIC mutation , *MYELODYSPLASTIC syndromes , *PEPTIDES , *PROTEINS , *RESEARCH funding , *RNA - Abstract
Recurrent mutations in the gene encoding additional sex combs-like 1 (ASXL1) are found in various hematologic malignancies and associated with poor prognosis. In particular, ASXL1 mutations are common in patients with hematologic malignancies associated with myelodysplasia, including myelodysplastic syndromes (MDSs), and chronic myelomonocytic leukemia. Although loss-of-function ASXL1 mutations promote myeloid transformation, a large subset of ASXL1 mutations is thought to result in stable truncation of ASXL1. Here we demonstrate that C-terminal–truncating Asxl1 mutations (ASXL1-MTs) inhibited myeloid differentiation and induced MDS-like disease in mice. ASXL1-MT mice displayed features of human-associated MDS, including multi-lineage myelodysplasia, pancytopenia, and occasional progression to overt leukemia. ASXL1-MT resulted in derepression of homeobox A9 (Hoxa9) and microRNA-125a (miR-125a) expression through inhibition of polycomb repressive complex 2–mediated (PRC2-mediated) methylation of histone H3K27. miR-125a reduced expression of C-type lectin domain family 5, member a (Clec5a), which is involved in myeloid differentiation. In addition, HOXA9 expression was high in MDS patients with ASXL1-MT, while CLEC5A expression was generally low. Thus, ASXL1-MT–induced MDS-like disease in mice is associated with derepression of Hoxa9 and miR-125a and with Clec5a dysregulation. Our data provide evidence for an axis of MDS pathogenesis that implicates both ASXL1 mutations and miR-125a as therapeutic targets in MDS. [ABSTRACT FROM AUTHOR]
- Published
- 2013
162. The effect of different apheresis modalities on coagulation factor XIII level during antibody removal in ABO-blood type incompatible living related renal transplantation.
- Author
-
Hanafusa, Norio, Hamasaki, Yoshifumi, Kawarasaki, Hiroo, Kido, Ryo, Shibagaki, Yugo, Ishikawa, Akira, Enomoto, Yutaka, Fujita, Toshiro, Noiri, Eisei, and Nangaku, Masaomi
- Subjects
- *
HEMAPHERESIS , *BLOOD coagulation , *IMMUNOGLOBULINS , *ABO blood group system , *KIDNEY transplantation , *PLASMAPHERESIS , *HEMORRHAGE complications - Abstract
Abstract: Apheresis therapy is used to remove pathogenic antibodies within the recipient blood during ABO-incompatible living related renal transplantation (LRRT). Factor XIII (FXIII) is a coagulating factor. Its deficiency reportedly engenders perioperative bleeding. This study compared apheresis modalities from the perspective of the FXIII level. Cases 1–3 were treated only with double-filtration plasmapheresis (DFPP) without (case 1) or with (cases 2 and 3) fresh frozen plasma (FFP) supplementation. Cases 4 and 5 were treated with simple plasma exchange (PEx) with FFP supplementation for the last session. Cases 1–3 showed a marked (case 1, 8.6%) or moderate (case 2, 26.2%; case 3, 28.4%) decrease in FXIII on the day before the procedure after the last apheresis session, although cases 4 (81.9%) and 5 (66.2%) did not. Case 1 experienced perioperative bleeding. The last session is usually performed the day before the surgical procedure. Therefore, FXIII elimination by DFPP might cause bleeding complications because of its slow recovery. The fact warrants that the last apheresis modality during the course might be PEx from the viewpoint of FXIII depletion. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
163. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study.
- Author
-
Taguchi, Satoru, Nakagawa, Tohru, Matsumoto, Akihiko, Nagase, Yasushi, Kawai, Taketo, Tanaka, Yoshinori, Yoshida, Kanae, Yamamoto, Sachi, Enomoto, Yutaka, Nose, Yorito, Sato, Toshikazu, Ishikawa, Akira, Uemura, Yukari, Fujimura, Tetsuya, Fukuhara, Hiroshi, Kume, Haruki, and Homma, Yukio
- Subjects
- *
NEUTROPHILS , *LYMPHOCYTE count , *PROGRESSION-free survival , *TRANSITIONAL cell carcinoma , *METASTASIS , *CANCER chemotherapy , *THERAPEUTICS - Abstract
Objectives To evaluate the prognostic significance of the pretreatment neutrophil-to-lymphocyte ratio in patients with metastatic urothelial carcinoma who underwent salvage chemotherapy. Methods We reviewed 200 metastatic urothelial carcinoma patients who received salvage chemotherapy at our five affiliate institutions between 2003 and 2011. The associations of pretreatment clinicopathological factors, including neutrophil-to-lymphocyte ratio, with cancer-specific survival and overall survival from the start of chemotherapy were assessed. Cox proportional hazards model was used for multivariate analysis. Results A total of 15 cases with missing data were excluded. Among the remaining 185 patients, 157 died during follow up, with a median survival of 13.0 months. Multivariate analysis showed that the pretreatment neutrophil-to-lymphocyte ratio ≥3, Eastern Cooperative Oncology Group performance status ≥2 and liver metastasis were independent poor prognostic factors, both for cancer-specific survival and overall survival. A prognostic model predicting overall survival was constructed based on the number of these three variables (0, 1 and ≥ 2). The classified patients showed significantly different overall survival (each P < 0.0001, log-rank test), with Harrell's concordance index as high as 0.81. Conclusions Pretreatment neutrophil-to-lymphocyte ratio elevation was an independent poor prognostic factor for metastatic urothelial carcinoma undergoing salvage chemotherapy. Our newly constructed prognostic model including the pretreatment neutrophil-to-lymphocyte ratio proved to be an excellent discriminator of overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
164. SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation.
- Author
-
Chang YH, Yamamoto K, Fujino T, Wang TW, Sugimoto E, Zhang W, Yabushita T, Suzaki K, Pietsch EC, Weir BA, Crescenzo R, Cowley GS, Attar R, Philippar U, Wunderlich M, Mizukawa B, Zheng Y, Enomoto Y, Imai Y, Kitamura T, and Goyama S
- Subjects
- Animals, Mice, Humans, Mice, Inbred C57BL, Cell Line, Tumor, Immunologic Surveillance, Monocytes metabolism, Monocytes immunology, Apoptosis, Leukemia, Myeloid, Acute pathology, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute metabolism, Leukemia, Myeloid, Acute genetics, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Cell Differentiation, Histone-Lysine N-Methyltransferase metabolism, Histone-Lysine N-Methyltransferase genetics
- Abstract
Monocytic acute myeloid leukemia (AML) responds poorly to current treatments, including venetoclax-based therapy. We conducted in vivo and in vitro CRISPR-Cas9 library screenings using a mouse monocytic AML model and identified SETDB1 and its binding partners (ATF7IP and TRIM33) as crucial tumor promoters in vivo. The growth-inhibitory effect of Setdb1 depletion in vivo is dependent mainly on natural killer (NK) cell-mediated cytotoxicity. Mechanistically, SETDB1 depletion upregulates interferon-stimulated genes and NKG2D ligands through the demethylation of histone H3 Lys9 at the enhancer regions, thereby enhancing their immunogenicity to NK cells and intrinsic apoptosis. Importantly, these effects are not observed in non-monocytic leukemia cells. We also identified the expression of myeloid cell nuclear differentiation antigen (MNDA) and its murine counterpart Ifi203 as biomarkers to predict the sensitivity of AML to SETDB1 depletion. Our study highlights the critical and selective role of SETDB1 in AML with granulo-monocytic differentiation and underscores its potential as a therapeutic target for current unmet needs., Competing Interests: Declaration of interests T.K. has received research support from Janssen Research and Development for this study. E.C.P., R.C., G.S.C., B.A.W., R.A., and U.P. are employees of Janssen Research and Development., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
165. Development of risk-score model in patients with negative surgical margin after robot-assisted radical prostatectomy.
- Author
-
Yamada Y, Fujii Y, Kakutani S, Kimura N, Sugimoto K, Hakozaki Y, Sugihara T, Takeshima Y, Kawai T, Nakamura M, Kamei J, Taguchi S, Akiyama Y, Sato Y, Yamada D, Urabe F, Miyazaki H, Enomoto Y, Fukuhara H, Nakagawa T, Fujimura T, and Kume H
- Subjects
- Male, Humans, Margins of Excision, Prostatectomy methods, Risk Factors, Retrospective Studies, Prostate-Specific Antigen, Robotics, Robotic Surgical Procedures adverse effects
- Abstract
A total of 739 patients underwent RARP as initial treatment for PCa from November 2011 to October 2018. Data on BCR status, clinical and pathological parameters were collected from the clinical records. After excluding cases with neoadjuvant and/or adjuvant therapies, presence of lymph node or distant metastasis, and positive SM, a total of 537 cases were eligible for the final analysis. The median follow-up of experimental cohort was 28.0 (interquartile: 18.0-43.0) months. We identified the presence of International Society of Urological Pathology grade group (ISUP-GG) ≥ 4 (Hazard ratio (HR) 3.20, 95% Confidence Interval (95% CI) 1.70-6.03, P < 0.001), lymphovascular invasion (HR 2.03, 95% CI 1.00-4.12, P = 0.049), perineural invasion (HR 10.7, 95% CI 1.45-79.9, P = 0.020), and maximum tumor diameter (MTD) > 20 mm (HR 1.9, 95% CI 1.01-3.70, P = 0.047) as significant factors of BCR in the multivariate analysis. We further developed a risk model according to these factors. Based on this model, 1-year, 3-year, and 5-year BCR-free survival were 100%, 98.9%, 98.9% in the low-risk group; 99.1%, 94.1%, 86.5% in the intermediate-risk group; 93.9%, 84.6%, 58.1% in the high-risk group. Internal validation using the bootstrap method showed a c-index of 0.742 and an optimism-corrected c-index level of 0.731. External validation was also carried out using an integrated database derived from 3 other independent institutions including a total of 387 patients for the final analysis. External validation showed a c-index of 0.655. In conclusion, we identified risk factors of biochemical failure in patients showing negative surgical margin after RARP and further developed a risk model using these risk factors., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
166. Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia.
- Author
-
Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, and Goyama S
- Subjects
- Animals, Mice, Mice, Knockout, Mice, Inbred C57BL, T-Lymphocytes, DNA-Binding Proteins genetics, Killer Cells, Natural, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute pathology
- Abstract
Immunotherapy has attracted considerable attention as a therapeutic strategy for cancers including acute myeloid leukemia (AML). In this study, we found that the development of several aggressive subtypes of AML is slower in Rag2
-/- mice despite the lack of B and T lymphocytes, even compared to the immunologically normal C57BL/6 mice. Furthermore, an orally active p53-activating drug shows stronger antileukemia effect on AML in Rag2-/- mice than C57BL/6 mice. Intriguingly, Natural Killer (NK) cells in Rag2-/- mice are increased in number, highly express activation markers, and show increased cytotoxicity to leukemia cells in a coculture assay. B2m depletion that triggers missing-self recognition of NK cells impairs the growth of AML cells in vivo. In contrast, NK cell depletion accelerates AML progression in Rag2-/- mice. Interestingly, immunogenicity of AML keeps changing during tumor evolution, showing a trend that the aggressive AMLs generate through serial transplantations are susceptible to NK cell-mediated tumor suppression in Rag2-/- mice. Thus, we show the critical role of NK cells in suppressing the development of certain subtypes of AML using Rag2-/- mice, which lack functional lymphocytes but have hyperactive NK cells., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF
167. Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
- Author
-
Taguchi S, Kawai T, Ambe Y, Kishitani K, Sugimoto K, Miyakawa J, Nakamura Y, Noda M, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Furuya Y, Sato Y, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, and Kume H
- Subjects
- Humans, Platinum therapeutic use, Propensity Score, Urinary Bladder Neoplasms pathology, Carcinoma, Transitional Cell drug therapy
- Abstract
Objective: Enfortumab vedotin (EV) was approved for advanced urothelial carcinoma (UC) in 2021 after the EV-301 trial showed its superiority to non-platinum-based chemotherapy as later-line treatment after platinum-based chemotherapy and immune checkpoint inhibitors including pembrolizumab. However, no study has compared EV with rechallenging platinum-based chemotherapy (i.e., "platinum rechallenge") in that setting., Methods: In total, 283 patients received pembrolizumab for advanced UC after platinum-based chemotherapy between 2018 and 2023. Of them, 41 and 25 patients received EV and platinum rechallenge, respectively, as later-line treatment after pembrolizumab. After excluding two patients with EV without imaging evaluation, we compared oncological outcomes, including progression-free survival (PFS) and overall survival (OS), between the EV (n = 39) and platinum rechallenge groups (n = 25) using propensity score matching (PSM)., Results: Analyses on crude data (n = 64) showed no significant differences between the two groups regarding patients' baseline characteristics. PFS (5 months) and OS (11 months) in the EV group were comparable to those (8 and 12 months, respectively) in the platinum rechallenge group. After PSM (n = 36), the baseline characteristics between the two groups became more balanced, and PFS (not reached) and OS (not reached) in the EV group were comparable to those (8 and 11 months, respectively) in the platinum rechallenge group., Conclusions: EV and platinum rechallenge showed equivalent oncological outcomes, even after PSM, and both treatments should therefore be effective treatment options for post-platinum, post-pembrolizumab advanced UC., (© 2023 The Japanese Urological Association.)
- Published
- 2023
- Full Text
- View/download PDF
168. Distinct use of super-enhancer elements controls cell type-specific CD25 transcription and function.
- Author
-
Spolski R, Li P, Chandra V, Shin B, Goel S, Sakamoto K, Liu C, Oh J, Ren M, Enomoto Y, West EE, Christensen SM, Wan ECK, Ge M, Lin JX, Yan B, Kazemian M, Yu ZX, Nagao K, Vijayanand P, Rothenberg EV, and Leonard WJ
- Subjects
- Animals, Mice, Enhancer Elements, Genetic genetics, Interleukin-2 Receptor alpha Subunit genetics, Interleukin-2 Receptor alpha Subunit metabolism, Receptors, Interleukin-2, Interleukin-2 genetics, Interleukin-2 pharmacology, STAT5 Transcription Factor genetics, STAT5 Transcription Factor metabolism
- Abstract
The IL-2 receptor α chain (IL-2Rα/CD25) is constitutively expressed on double-negative (DN2/DN3 thymocytes and regulatory T cells (T
regs ) but induced by IL-2 on T and natural killer (NK) cells, with Il2ra expression regulated by a STAT5-dependent super-enhancer. We investigated CD25 regulation and function using a series of mice with deletions spanning STAT5-binding elements. Deleting the upstream super-enhancer region mainly affected constitutive CD25 expression on DN2/DN3 thymocytes and Tregs , with these mice developing autoimmune alopecia, whereas deleting an intronic region decreased IL-2-induced CD25 on peripheral T and NK cells. Thus, distinct super-enhancer elements preferentially control constitutive versus inducible expression in a cell type-specific manner. The mediator-1 coactivator colocalized with specific STAT5-binding sites. Moreover, both upstream and intronic regions had extensive chromatin interactions, and deletion of either region altered the super-enhancer structure in mature T cells. These results demonstrate differential functions for distinct super-enhancer elements, thereby indicating previously unknown ways to manipulate CD25 expression in a cell type-specific fashion.- Published
- 2023
- Full Text
- View/download PDF
169. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
- Author
-
Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, Yamamoto K, Sato N, Enomoto Y, Tanaka Y, Fukuyama T, Satoh H, Kato K, Saitoh K, Ishikawa T, Soga T, Nannya Y, Fukagawa T, Nakanishi M, Kitagawa D, Kitamura T, and Goyama S
- Subjects
- Humans, Decitabine pharmacology, Decitabine therapeutic use, Antimetabolites, Antineoplastic pharmacology, DNA Methylation genetics, DNA, Adaptor Proteins, Signal Transducing genetics, Azacitidine pharmacology, Azacitidine therapeutic use, Leukemia, Myeloid, Acute pathology
- Abstract
Decitabine (DAC) is clinically used to treat myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Our genome-wide CRISPR-dCas9 activation screen using MDS-derived AML cells indicates that mitotic regulation is critical for DAC resistance. DAC strongly induces abnormal mitosis (abscission failure or tripolar mitosis) in human myeloid tumors at clinical concentrations, especially in those with TP53 mutations or antecedent hematological disorders. This DAC-induced mitotic disruption and apoptosis are significantly attenuated in DNMT1-depleted cells. In contrast, overexpression of Dnmt1, but not the catalytically inactive mutant, enhances DAC-induced mitotic defects in myeloid tumors. We also demonstrate that DAC-induced mitotic disruption is enhanced by pharmacological inhibition of the ATR-CLSPN-CHK1 pathway. These data challenge the current assumption that DAC inhibits leukemogenesis through DNMT1 inhibition and subsequent DNA hypomethylation and highlight the potent activity of DAC to disrupt mitosis through aberrant DNMT1-DNA covalent bonds., Competing Interests: Declaration of interests The authors declare no potential conflicts of interest., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
170. Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
- Author
-
Taguchi S, Kawai T, Buti S, Bersanelli M, Uemura Y, Kishitani K, Miyakawa J, Sugimoto K, Nakamura Y, Niimi F, Kaneko T, Kamei J, Obinata D, Yamaguchi K, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Nakagawa T, Takahashi S, and Kume H
- Subjects
- Humans, Antibodies, Monoclonal, Humanized therapeutic use, Prognosis, Retrospective Studies, Carcinoma, Transitional Cell drug therapy, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms drug therapy
- Abstract
Aim: To validate a 'drug score' that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). Materials & methods: We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab. Results: The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC. Conclusion: A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.
- Published
- 2023
- Full Text
- View/download PDF
171. Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study.
- Author
-
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Taguchi S, Tabata M, Kaneko T, Ishikawa A, Miyazaki H, Kondo Y, Matsumoto A, Naito A, Hikatsu M, Fujii Y, Akiyama Y, Yamada Y, Sato Y, Nomiya A, Yamada D, Murata T, Suzuki M, Enomoto Y, Nishimatsu H, Takeuchi T, Tanaka Y, and Kume H
- Subjects
- Humans, Aged, Retrospective Studies, Prognosis, Nephroureterectomy methods, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms surgery, Urologic Neoplasms pathology
- Abstract
Purpose: The prognosis of patients with pT3 upper tract urothelial carcinoma (UTUC) varies. The current study aimed to further classify patients with pT3 UTUC into different survival outcome groups based on tumor location and site of invasion., Methods: This retrospective study included 323 patients with pT3 UTUC who underwent nephroureterectomy at 11 hospitals in Japan. Histological and clinical data were obtained via a chart review. Univariate and multivariate Cox proportional hazards analyses showed the effect of different variables on recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS)., Results: The median age of the patients was 72 years. Patients with pT3 UTUCs were divided into two groups: those with renal parenchymal invasion only (pT3a, n = 95) and those with peripelvic or periureteral fat invasion (pT3b, n = 228). pT3b UTUC was significantly associated with hydronephrosis, low preoperative estimated glomerular filtration rate (eGFR), histological nodal metastasis, nuclear grade 3, lymphovascular invasion (LVI), carcinoma in situ, and positive surgical margin. Based on the univariate analyses, patients with pT3b UTUC had a significantly lower 5-year RFS (42.4% vs. 70.1%, p < 0.0001), 5-year CSS (54.3% vs. 80.0%, p = 0.0002), and 5-year OS (47.8% vs. 76.8%, p < 0.0001) than those with pT3a UTUC. According to the multivariate analyses, nodal metastasis, LVI, adjuvant chemotherapy, preoperative eGFR, nuclear grade (RFS only), surgical margin (RFS only), and Charlson comorbidity index (OS only), but not pT3b stage, were associated with survival., Conclusion: Compared with pT3a UTUC, pT3b UTUC was significantly associated with worse histological features, consequently resulting in unsatisfactory survival outcomes., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
172. Improved survival in real-world patients with advanced urothelial carcinoma: A multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020).
- Author
-
Taguchi S, Kawai T, Nakagawa T, Miyakawa J, Kishitani K, Sugimoto K, Nakamura Y, Kamei J, Obinata D, Yamaguchi K, Kaneko T, Yoshida K, Yamamoto S, Kakutani S, Kanazawa K, Sugihara Y, Tokunaga M, Matsumoto A, Uemura Y, Akiyama Y, Yamada Y, Sato Y, Yamada D, Enomoto Y, Nishimatsu H, Ishikawa A, Tanaka Y, Nagase Y, Fujimura T, Fukuhara H, Takahashi S, and Kume H
- Subjects
- Humans, Propensity Score, Retrospective Studies, Cohort Studies, Carcinoma, Transitional Cell pathology, Urinary Bladder Neoplasms pathology
- Abstract
Objectives: Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study aimed to assess (1) the improvement in survival among real-world patients with aUC after the introduction of pembrolizumab and (2) the direct survival-prolonging effect of pembrolizumab., Methods: This multicenter retrospective study included 531 patients with aUC undergoing salvage chemotherapy, including 200 patients treated in the pre-pembrolizumab era (2003-2011; earlier era) and 331 patients treated in a recent 5-year period (2016-2020; recent era). Using propensity score matching (PSM), cancer-specific survival (CSS) and overall survival (OS) were compared between the earlier and recent eras, in addition to between the recent era, both with and without pembrolizumab use, and the earlier era., Results: After PSM, the recent era cohort had significantly longer CSS (21 months) and OS (19 months) than the earlier era cohort (CSS and OS: 12 months). In secondary analyses using PSM, patients treated with pembrolizumab had significantly longer CSS (25 months) and OS (24 months) than those in the earlier era cohort (CSS and OS: 11 months), whereas patients who did not receive pembrolizumab in the recent era had similar outcomes (CSS and OS: 14 months) as the earlier era cohort (CSS and OS: 12 months)., Conclusions: Patients with aUC treated in the recent era exhibited significantly longer survival than those treated before the introduction of pembrolizumab. The improved survival was primarily attributable to the use of pembrolizumab., (© 2022 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.)
- Published
- 2022
- Full Text
- View/download PDF
173. Cytokine-enhanced cytolytic activity of exosomes from NK Cells.
- Author
-
Enomoto Y, Li P, Jenkins LM, Anastasakis D, Lyons GC, Hafner M, and Leonard WJ
- Subjects
- Cytokines metabolism, Cytotoxicity, Immunologic, Humans, Interleukin-15 metabolism, Killer Cells, Natural, Exosomes, Extracellular Vesicles metabolism
- Abstract
Natural killer (NK) cells play key roles in immune surveillance against tumors and viral infection. NK cells distinguish abnormal cells from healthy cells by cell-cell interaction with cell surface proteins and then attack target cells via multiple mechanisms. In addition, extracellular vesicles (EVs) derived from NK cells (NK-EVs), including exosomes, possess cytotoxic capacity against tumor cells, but their characteristics and regulation by cytokines remain unknown. Here, we report that EVs derived from human NK-92 cells stimulated with IL-15 + IL-21 show enhanced cytotoxic capacity against tumor cells. Major cytolytic granules, granzyme B and granzyme H, are enriched by IL-15 + IL-21 stimulation in NK-EVs; however, knockout experiments reveal those cytolytic granules are independent of enhanced cytotoxic capacity. To find out the key molecules, mass spectrometry analyses were performed with different cytokine conditions, no cytokine, IL-15, IL-21, or IL-15 + IL-21. We then found that CD226 (DNAM-1) on NK-EVs is enriched by IL-15 + IL-21 stimulation and that blocking antibodies against CD226 reduced the cytolytic activity of NK-EVs. We also show NK-EVs are taken up by target cells via macropinocytosis. Collectively, our findings elucidate the novel properties of NK-EVs and the mechanism of their incorporation into target cells., (© 2021. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021.)
- Published
- 2022
- Full Text
- View/download PDF
174. New Technique for Introducing a Surgical Stapler during Robot-Assisted Lobectomy for Lung Cancer.
- Author
-
Usuda J, Inoue T, Sonokawa T, Matsumoto M, Enomoto Y, Suzuki K, and Tomioka Y
- Subjects
- Humans, Retrospective Studies, Surgical Staplers, Lung Neoplasms surgery, Robotic Surgical Procedures methods, Robotics
- Abstract
Background: The da Vinci Si version robot lacks a vascular stapler that can be controlled by the operating surgeon at the surgical console when dividing pulmonary vessels. Therefore, to initiate and safely perform robotic anatomical lobectomy for lung cancer, it is important to develop a safe method for introducing a surgical stapler., Methods: We performed a retrospective study of the first 42 consecutive patients who underwent robotic lobectomy for lung cancer at Nippon Medical School Hospital between January 2019 and December 2020., Results: Up to case 18, we performed robot-assisted thoracoscopic surgery (RATS) lobectomy by using a four-arm approach with two assistant ports. For dividing pulmonary vessels, the surgical stapler was introduced through the assist ports. However, since this is not the port position usually used in video-assisted thoracoscopic surgery (VATS), there were many difficult situations. For RATS lobectomy case 19 and all subsequent cases, we utilized a total port approach that uses three robotic arms and two assistant ports. To resect the pulmonary vessels or bronchi with endoscopic staplers, the port for the robotic arm was removed and the endoscopic staplers were placed through a 12-mm Xcel bladeless port. This change reduced operation time, blood loss, and robotic arm interference. No patient developed intraoperative complications during RATS lobectomy., Conclusion: The present total port approach, with three robotic arms, appears to be feasible for introducing surgical staplers during RATS with the da Vinci Si robotic system.
- Published
- 2022
- Full Text
- View/download PDF
175. Clinical characteristics of patients with inguinal hernia mesh migration into the bladder.
- Author
-
Akimoto T, Kakutani S, Kamei J, Kume H, Fujimura T, and Enomoto Y
- Abstract
Introduction: We report two cases of mesh migration into the bladder after inguinal hernia surgery., Case Presentation: In the first case, a 48-year-old woman who underwent right internal inguinal hernia repair, 18 months prior, presented with pollakiuria and microscopic hematuria that was resistant to antibiotics. A submucosal tumor was detected at the bladder dome by cystoscopy, and transurethral resection was performed. Intraoperatively, a migrated mesh was observed in the submucosal lesion. In the second case, a 55-year-old man who underwent a right external inguinal hernia repair, approximately 14 years prior, presented with persistent microscopic hematuria and pyuria. Cystoscopy revealed mesh migration to the upper right bladder wall. Both patients underwent partial cystectomy with mesh removal, and their complaints were resolved after surgery., Conclusion: Mesh migration should be suspected in patients with a history of inguinal hernia repair, accompanied by persistent lower urinary tract symptoms or abnormal urinalysis findings., Competing Interests: The authors declare no conflicts of interest., (© 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.)
- Published
- 2022
- Full Text
- View/download PDF
176. CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression.
- Author
-
Liu X, Sato N, Shimosato Y, Wang TW, Denda T, Chang YH, Yabushita T, Fujino T, Asada S, Tanaka Y, Fukuyama T, Enomoto Y, Ota Y, Sakamoto T, Kitamura T, and Goyama S
- Subjects
- Animals, CD8-Positive T-Lymphocytes metabolism, Hematopoiesis genetics, Mice, Mutation, Transcription Factors genetics, Tumor Microenvironment, Clonal Hematopoiesis genetics, Neoplasms, Repressor Proteins genetics, Repressor Proteins metabolism
- Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is an age-associated phenomenon characterized by clonal expansion of blood cells harboring somatic mutations in hematopoietic genes, including DNMT3A, TET2, and ASXL1. Clinical evidence suggests that CHIP is highly prevalent and associated with poor prognosis in solid-tumor patients. However, whether blood cells with CHIP mutations play a causal role in promoting the development of solid tumors remained unclear. Using conditional knock-in mice that express CHIP-associated mutant Asxl1 (Asxl1-MT), we showed that expression of Asxl1-MT in T cells, but not in myeloid cells, promoted solid-tumor progression in syngeneic transplantation models. We also demonstrated that Asxl1-MT-expressing blood cells accelerated the development of spontaneous mammary tumors induced by MMTV-PyMT. Intratumor analysis of the mammary tumors revealed the reduced T-cell infiltration at tumor sites and programmed death receptor-1 (PD-1) upregulation in CD8
+ T cells in MMTV-PyMT/Asxl1-MT mice. In addition, we found that Asxl1-MT induced T-cell dysregulation, including aberrant intrathymic T-cell development, decreased CD4/CD8 ratio, and naïve-memory imbalance in peripheral T cells. These results indicate that Asxl1-MT perturbs T-cell development and function, which contributes to creating a protumor microenvironment for solid tumors. Thus, our findings raise the possibility that ASXL1-mutated blood cells exacerbate solid-tumor progression in ASXL1-CHIP carriers., (© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2022
- Full Text
- View/download PDF
177. Intravascular large B-cell lymphoma in renal cell carcinoma incidentally detected by robot-assisted partial nephrectomy.
- Author
-
Noda M, Enomoto Y, Shirasugi Y, Ando S, Matsuzawa Y, and Kume H
- Abstract
Introduction: Intravascular large B-cell lymphoma is a rare and aggressive type of extranodal large B-cell lymphoma. Although intravascular large B-cell lymphoma can invade various organs, renal involvement has been rarely reported. Synchronous occurrence of intravascular lymphoma with renal cell carcinoma is extremely rare. We herein report a case of intravascular large B-cell lymphoma in a renal cell carcinoma incidentally detected by robot-assisted partial nephrectomy., Case Presentation: A 69-year-old female with recurrent fever lasting 4 years underwent robot-assisted partial nephrectomy for small renal cell carcinoma. Histological findings led to the diagnosis of intravascular large B-cell lymphoma, which involved the normal tissue of right kidney as well as clear cell renal cell carcinoma. She received six cycles of chemotherapy without major complications and achieved complete remission., Conclusion: We encountered a rare case of synchronous intravascular lymphoma with renal cell carcinoma., Competing Interests: The authors declare no conflict of interest., (© 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.)
- Published
- 2022
- Full Text
- View/download PDF
178. Impact of immune-related adverse events on the therapeutic efficacy of pembrolizumab in urothelial carcinoma: a multicenter retrospective study using time-dependent analysis.
- Author
-
Kawai T, Taguchi S, Nakagawa T, Kamei J, Nakamura Y, Obinata D, Yamaguchi K, Kaneko T, Kakutani S, Tokunaga M, Uemura Y, Sato Y, Enomoto Y, Nishimatsu H, Fujimura T, Fukuhara H, Takahashi S, and Kume H
- Subjects
- Aged, Antibodies, Monoclonal, Humanized pharmacology, Antineoplastic Agents, Immunological pharmacology, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Prognosis, Retrospective Studies, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Urinary Bladder Neoplasms drug therapy
- Abstract
Background: Several studies have reported the incidence of immune-related adverse events (irAEs) as a predictor of the efficacy of anti-programmed cell death protein 1 antibodies in patients with cancer. However, immortal time bias has not always been fully addressed in these studies. In this retrospective multicenter study, we assessed the association between the incidence of irAEs and the efficacy of pembrolizumab in urothelial carcinoma (UC) using time-dependent analysis, an established statistical method to minimize immortal time bias., Methods: The study included 176 patients with advanced UC who underwent pembrolizumab treatment at seven affiliated institutions between January 2018 and July 2020. Patients with irAEs were compared with those without irAEs in terms of overall survival (OS) and cancer-specific survival (CSS). Immortal time bias was eliminated by using time-dependent analysis., Results: Of the 176 patients, irAEs occurred in 77 patients (43.8%), with a median of 60 days. The irAEs (+) cohort showed significantly favorable OS and CSS compared with the irAEs (-) cohort (p=0.018 and p=0.005, respectively), especially in the cohort with grade 1-2 irAEs (OS and CSS; p=0.003 and p=0.002, respectively). Multivariate analyses identified any irAEs and grade 1-2 irAEs as independent favorable prognostic factors for OS and CSS., Conclusion: Even after minimizing immortal time bias by time-dependent analysis, the incidence of irAEs, especially grade 1-2 irAEs, could be a significant predictor of favorable prognoses in patients with UC who have undergone pembrolizumab treatment., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
179. Smaller decline of renal function after nephroureterectomy predicts poorer prognosis of upper tract urothelial carcinoma: a multicentre retrospective study.
- Author
-
Yamada Y, Nakagawa T, Miyakawa J, Kawai T, Tabata M, Kaneko T, Taguchi S, Naito A, Hikatsu M, Sato Y, Murata T, Matsumoto A, Miyazaki H, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Takeuchi T, Tanaka Y, and Kume H
- Subjects
- Aged, Humans, Kidney physiology, Kidney surgery, Neoplasm Recurrence, Local, Nephrectomy, Nephroureterectomy, Prognosis, Retrospective Studies, Carcinoma, Transitional Cell surgery, Ureteral Neoplasms surgery, Urinary Bladder Neoplasms
- Abstract
Purpose: Renal function is frequently impaired in the patients with upper tract urothelial carcinoma. We aimed to evaluate the impact of renal function and its change after surgery on survival rates in patients with upper tract urothelial carcinoma after nephroureterectomy., Methods: The study cohort comprised 755 patients with upper tract urothelial carcinoma who underwent nephroureterectomy between 1995 and 2016 at nine hospitals in Japan. Estimated glomerular filtration rate was calculated using the three-variable Japanese equation for glomerular filtration rate estimation from serum creatinine level and age. Outcomes were recurrence-free, cancer-specific and overall survivals. Univariate and multivariate Cox proportional hazards regression analyses were used., Results: Median patients' age was 72 years old. Pre- and post-surgical median estimated glomerular filtration rate were 55.5 and 42.9 ml/min/1.73 m2, respectively. Median estimated glomerular filtration rate decline after surgery, which represents function of the affected side kidney, was 13.1 ml/min/1.73 m2. The 5-year recurrence-free, cancer-specific and overall survivals were 68.3, 79.4 and 74.0%, respectively. Multivariate analysis indicated that lower preoperative estimated glomerular filtration rate and estimated glomerular filtration rate decline were associated with poorer recurrence-free, cancer-specific and overall survivals, but post-operative estimated glomerular filtration rate was not. Estimated glomerular filtration rate decline was more significant poor-prognosticator than preoperative estimated glomerular filtration rate. Proportions of the patients with estimated glomerular filtration rate <60 ml/min/1.73 m2 before surgery were 50.6 and 73.2% in organ-confined disease and locally advanced disease, respectively (P < 0.0001). After surgery, they were 91.6 and 89.8%, respectively (P = 0.3896)., Conclusions: Lower preoperative renal function, especially of the affected side kidney, was significantly associated with poor prognosis after nephroureterectomy for upper tract urothelial carcinoma. Many patients with locally advanced disease have reduced renal function at diagnosis and even more after surgery., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
180. Usefulness of simultaneous type image-enhanced endoscope system in photodynamic therapy for centrally located lung cancer.
- Author
-
Sonokawa T, Matsumoto M, Takegahara K, Inoue T, Enomoto Y, and Usuda J
- Subjects
- Endoscopes, Humans, Light, Photosensitizing Agents therapeutic use, Lung Neoplasms diagnostic imaging, Lung Neoplasms drug therapy, Photochemotherapy methods
- Abstract
Background: Photodynamic therapy (PDT) is established as one of the standard treatment options for centrally located early lung cancer. In order to improve the effectiveness of PDT, it is very important to accurately diagnose the extent of the tumor and focus the laser irradiation accurately. With the use of the conventional video-endoscope system, which adopts the frame-sequential (RGB-based) display method, mainly used in Japan, for PDT laser irradiation, the system only recognizes the strong white light, and color information is lost. Therefore, it is difficult to irradiate the lesion while simultaneously observing the lesion. In this study, we investigated the usefulness of a new type of video-endoscope system during PDT., Methods: We used ELUXEO 7000® (FUJIFILM, Japan), which is a simultaneous-type video-endoscope system that has been in use at Nippon Medical School Hospital since October 2018. We analyzed the clinical usefulness of the ELUXEO® system for PDT as compared to other endoscope systems, such as EVIS LUCERA ELITE® (Olympus, Japan), an autofluorescence imaging (AFI) system., Results: After the administration of talaporfin sodium for PDT, the tumor lesion was not visualized in magenta color with AFI, yielding false-negative results. On the other hand, no false-negative results after the administration of talaporfin sodium were obtained with the use of ELUXEO®. Using the ELUXEO® system in the blue light imaging (BLI) mode, we were able to deliver a red laser light while observing the extent of the tumor. Missed laser exposure was avoided and the accuracy of PDT was improved with the use of this system., Conclusions: ELUXEO® is useful for accurate evaluation of the extent of centrally located lung cancer and therefore, for accurate laser irradiation of the tumor lesion., (Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
181. Clinical significance and risk factors of urethrovesical anastomotic urinary leakage following robot-assisted radical prostatectomy: a multi-institutional study.
- Author
-
Kakutani S, Takeshima Y, Yamada Y, Fujimura T, Nagamoto S, Enomoto Y, Hakozaki Y, Kimura N, Teshima T, Akiyama Y, Sato Y, Kawai T, Yamada D, and Kume H
- Subjects
- Aged, Anastomosis, Surgical, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Anastomotic Leak epidemiology, Prostatectomy methods, Prostatic Neoplasms surgery, Robotic Surgical Procedures, Urethra surgery, Urinary Bladder surgery
- Abstract
Background: There has been a limited number of reports on the significance and risk factors of urethrovesical anastomotic urinary leakage (AUL) following robot-assisted radical prostatectomy (RARP). We aimed to analyze the clinical significance of AUL and evaluated its risk factors., Methods: We conducted a multi-institutional study to review patients with prostate cancer undergoing RARP in three centers (The University of Tokyo Hospital, Mitsui Memorial Hospital, and Chiba Tokushukai Hospital). "Positive AUL" was defined as urinary extravasation at the anastomosis detected by post-operative cystogram and was further categorized into minor or major AUL. Univariate and multivariate analyses were performed to identify predictors of AUL. Postoperative continence rates and time to achieve continence were also analyzed., Results: A total of 942 patients underwent RARP for prostate cancer in 3 centers. Of these patients, a cystogram after the RARP procedure was not performed in 26 patients leaving 916 patients for the final analysis. AUL was observed in 56 patients (6.1%); 34 patients (3.7%) with minor AUL and 22 patients (2.4%) with major AUL. Patients with major AUL exhibited a significantly longer time to achieve continence than those without major AUL. Multivariate analysis demonstrated that longer console time (≥ 184 min) was significantly associated with overall AUL, and higher body mass index (≥ 25 g/kg
2 ) was a significant predictor of both major and overall AUL., Conclusions: The presence of major AUL was associated with the achievement of urinary continence, suggesting clinical relevance of its diagnosis by postoperative cystogram. A selective cystogram has been proposed for high-risk cases. Furthermore, identification of the risk factors of AUL will lead to optimal application.- Published
- 2021
- Full Text
- View/download PDF
182. [Therapeutic Strategies for Metachronous Multiple Primary Lung Cancer].
- Author
-
Usuda J, Matsumoto M, Suzuki K, Tomioka Y, Sonokawa T, Inoue T, and Enomoto Y
- Subjects
- Aged, Humans, Neoplasm Recurrence, Local, Quality of Life, Retrospective Studies, Lung Neoplasms surgery, Neoplasms, Multiple Primary surgery, Neoplasms, Second Primary surgery
- Abstract
Backgrounds: It is not uncommon to encounter metachronous primary lung cancer after surgical treatment along with the increase in the elderly patients. In consideration of increasing number of such patients, it is necessary to take various treatment strategies., Methods: In order to establish a treatment strategy for multiple lung cancer, we retrospectively examined multiple lung cancer cases operated for primary lung cancer in our department from January 2013 to December 2019, and the future treatment strategy was examined., Results: Of 821 patients who underwent surgery for primary lung cancer, 61 were multiple lung cancers, 31 were synchronous multiple lung cancers, and 30 were metachronous multiple lung cancers. Among the cases of metachronous multiple lung cancer, 28 cases had undergone lobectomy or more in the first operation, 1 case of segmental resection, and 1 case of partial resection. As for the treatment of secondary lung cancer lesions, 21 lesions were performed surgery( lobectomy;2, segmental resection;2, partial resection;17), 6 lesions of photodynamic therapy (PDT), and 3 lesions of stereotactic body radiation therapy (SBRT). Among the surgical cases, there were three cases on the same side as the first cancer and 18 cases on the opposite side. The three cases underwent partial resection. Among 21 patients, postoperative home oxygen therapy was introduced in 2 patients. Regarding the prognosis, three patients who had surgical resection, died of recurrence of the first lesion. One of the six PDT patients died of recurrence of the first lung cancer and another died of other disease. All three patients who underwent SBRT are alive without recurrence., Conclusions: If early detection and early diagnosis are made as a treatment strategy for metachronous multiple lung cancer, it may be possible to preserve lung function by reducing surgery or SBRT, PDT, and to cure without damaging the quality of life.
- Published
- 2021
183. A Case of Pulmonary Adenofibroma Treated by Thoracoscopic Resection.
- Author
-
Sonokawa T, Enomoto Y, Kunugi S, Terasaki Y, and Usuda J
- Subjects
- Adenofibroma diagnostic imaging, Adenofibroma pathology, Female, Humans, Lung Neoplasms diagnostic imaging, Lung Neoplasms pathology, Middle Aged, Neoplasm Recurrence, Local, Pulmonary Sclerosing Hemangioma, Treatment Outcome, Adenofibroma surgery, Lung Neoplasms surgery, Thoracic Surgery, Video-Assisted methods
- Abstract
Pulmonary adenofibroma is a rare biphasic tumor that contains epithelial and stromal components. We report a case of pulmonary adenofibroma in which the tumor was resected by thoracoscopic surgery and the diagnosis was established by histopathology. A 59-year-old woman with a past medical history of pyelonephritis visited our hospital for evaluation of an abnormal opacity on a plain chest x-ray during a comprehensive medical examination. A follow-up chest x-ray showed enlargement of the lesion, and the patient was referred to our department for further management. Chest computed tomography revealed a well-circumscribed nodule measuring 1.4 cm in diameter in the upper lobe of the left lung. The chest imaging findings suggested a benign tumor, but because of evidence of lesion enlargement and elevated serum carcinoembryonic antigen levels, we performed wide wedge resection of the left upper lobe by video-assisted thoracoscopic surgery, for diagnosis and treatment. The resected specimen was submitted for rapid pathological diagnosis during the operation, and a benign tumor, possibly sclerosing pneumocytoma, was suspected. Therefore, we completed the operation with wide wedge resection. The final histopathological diagnosis was pulmonary adenofibroma. The patient had an uneventful postoperative course, and at this writing, 6 months postoperatively, there has been no evidence of tumor recurrence. We have reported this case of pulmonary adenofibroma because the tumor is rare, has not yet been well-characterized, and has an unclear prognosis. Collection of data from a larger number of patients is necessary.
- Published
- 2021
- Full Text
- View/download PDF
184. A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic.
- Author
-
Enomoto Y, Namba Y, Hoshika Y, Komemushi Y, Mitani K, Kume H, Kobayashi E, Miyama Y, Homma Y, Ushiku T, and Seyama K
- Subjects
- Adult, Humans, Male, Birt-Hogg-Dube Syndrome genetics, Carcinoma, Renal Cell genetics, Kidney Neoplasms genetics, Proto-Oncogene Proteins genetics, Tumor Suppressor Proteins genetics
- Abstract
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominant cancer syndrome caused by a germline mutation of the folliculin (FLCN) gene. Previous studies have suggested that truncated mutant folliculin proteins generated by disease causing FLCN mutations may retain partial functionality and contribute to disease phenotype. A 38-year-old Russian man presented with a left renal tumor. He underwent a left radical nephrectomy and histological examination confirmed the diagnosis of chromophobe renal cell carcinoma. He had papulae on his face suggestive of fibrofolliculomas, and pulmonary cysts on his computed tomography of the chest. He had a family history of skin manifestations. Genetic analysis identified a genomic deletion including the putative promoter region of FLCN exon 1 in the germline, and the second hit on the remaining wild-type FLCN in the renal carcinoma cells, which is expected to cause the complete lack of folliculin protein. Immunohistochemistry with the use of anti-folliculin antibody showed no antibody-binding on chromophobe renal carcinoma cells. These findings suggest that the decreased FLCN expression itself without producing mutated folliculin proteins can be at risk for developing clinical manifestations of BHDS: fibrofolliculomas, lung cysts, and tumorigenesis in the kidneys. This sheds light on the pathogenesis of BHDS and the role of FLCN as a tumor suppressor gene., Competing Interests: Declaration of competing interest The authors declare that there is no conflict of interests regarding the publication of this study., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
185. Neutrophils alleviate fibrosis in the CCl 4 -induced mouse chronic liver injury model.
- Author
-
Saijou E, Enomoto Y, Matsuda M, Yuet-Yin Kok C, Akira S, Tanaka M, and Miyajima A
- Abstract
Tribbles pseudokinase 1 ( Trib1 ) is a negative regulator of CCAAT/enhancer binding protein α (C/EBPα) and is known to induce granulopoiesis while suppressing monocyte differentiation. Loss of Trib1 was previously shown to increase the neutrophil population in the spleen but lead to M2-like macrophage reduction. Because M2 macrophages are anti-inflammatory and promote tissue repair by producing fibrogenic factors, we investigated liver fibrosis in Trib1 -deficient mice. Interestingly, loss of Trib1 suppressed fibrosis in the CCl
4 -induced chronic liver injury model. Trib1 knockout increased neutrophils but had a minimal effect on the macrophage population in the liver. Hepatic expressions of neutrophil matrix metalloproteinases ( Mmp ) 8 and Mmp9 were increased, but the production of fibrogenic factors, including transforming growth factor β1, was not affected by loss of Trib1 . These results suggest that neutrophils are responsible for the suppression of fibrosis in Trib1 -deficient liver. Consistently, transplantation of Trib1 -deficient bone marrow cells into wild-type mice alleviated CCl4 -induced fibrosis. Furthermore, expression of chemokine (C-X-C motif) ligand 1 ( Cxcl1 ) by adeno-associated viral vector in the normal liver recruited neutrophils and suppressed CCl4 -induced fibrosis; infusion of wild-type neutrophils in CCl4 -treated mice also ameliorated fibrosis. Using recombinant adeno-associated virus-mediated expression of Mmp8 and Mmp9 alleviated liver fibrosis. Finally, neutrophil depletion by infusion of Ly6G antibody significantly enhanced CCl4 -induced fibrosis. Conclusion : While neutrophils are well known to exacerbate acute liver injury, our results demonstrate a beneficial role of neutrophils in chronic liver injury by promoting fibrolysis. ( Hepatology Communications 2018;2:703-717).- Published
- 2018
- Full Text
- View/download PDF
186. Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion.
- Author
-
Kuriyama K, Enomoto Y, Suzuki R, Watanuki J, Hosoi H, Yamashita Y, Murata S, Mushino T, Tamura S, Hanaoka N, Dyer M, Siebert R, Kiyonari H, Nakakuma H, Kitamura T, and Sonoki T
- Subjects
- Animals, Cell Differentiation genetics, Cell Line, Tumor, Humans, Mice, Transgenic, MicroRNAs metabolism, B-Lymphocytes pathology, Chromosomes, Human, Pair 14 genetics, Chromosomes, Human, Pair 8 genetics, Gene Expression genetics, Lymphoma, B-Cell genetics, MicroRNAs genetics, MicroRNAs physiology, Translocation, Genetic genetics
- Abstract
MicroRNA142 (MIR142) is a target of chromosome translocations and mutations in human B-cell lymphomas. We analyzed an aggressive B-cell lymphoma carrying t(8;17)(q24;q22) and t(6;14)(p21;q32), and sought to explore the role(s) of MIR142 in lymphomagenesis. t(8;17)(q24;q22) involved MYC on 8q24 and pri-MIR142 on 17q22. MYC was activated by a promoter substitution by t(8;17)(q24;q22). t(8;17)(q24;q22) was an additional event after t(6;14) (p21;q32), which caused the over-expression of CCND3. Southern blot analyses revealed that the MIR142 locus was deleted from the affected allele, whereas Northern analyses showed over-expression of MIR142 in tumor cells. Although previous studies reported an over-expression of mutations in MIR142 in B-cell lymphomas, limited information is available on the functions of MIR142 in lymphomagenesis. Therefore, we generated bone marrow transplantation (BMT) and transgenic (Eμ/mir142) mice, which showed enforced expression in hematopoietic progenitor cells and B cells, respectively. BMT mice showed decreased numbers of all lineage-positive cells, particularly B cells, in peripheral blood. Eμ/mir142 mice showed decreased numbers of IgM-positive splenocytes, and exhibited altered B-cell phenotypic changes induced by lipopolysaccharide. Our results suggest that over-expression of MIR142 alters B-cell differentiation, implying multi-step lymphomagenesis together with MYC activation and CCND3 over-expression.
- Published
- 2018
- Full Text
- View/download PDF
187. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate?
- Author
-
Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, and Homma Y
- Subjects
- Aged, Aged, 80 and over, C-Reactive Protein metabolism, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms secondary, Lymphatic Metastasis, Male, Metastasectomy, Middle Aged, Proportional Hazards Models, Retrospective Studies, Survival Rate, Time Factors, Treatment Outcome, Carcinoma, Transitional Cell secondary, Carcinoma, Transitional Cell surgery, Lung Neoplasms surgery, Lymph Node Excision, Patient Selection, Urologic Neoplasms pathology
- Abstract
Background: Resection of metastatic lesions (metastasectomy) is performed for highly selected patients with metastatic urothelial carcinoma (mUC). This study aimed to identify the clinicopathologic factors associated with oncologic outcome for patients who underwent metastasectomy for mUC., Methods: This analysis included 37 UC patients who underwent metastasectomy with curative intent at nine Japanese hospitals. The primary end point was cancer-specific survival. The Kaplan-Meier method with the log-rank test and the multivariable Cox proportional hazards model addressed the relationship between clinical characteristics and survival., Results: Metastasectomy was performed for pulmonary (n = 23), nodal (n = 7), and other (n = 7) metastases. The median survival time was 35.4 months (interquartile range [IQR] 15.5, not reached) from the detection of metastasis and 34.3 months (IQR 13.1, not reached) from metastasectomy. The 5-year cancer-specific survival rate after detection of metastasis was 39.7%. In the multivariate analysis, the time from primary surgery to detection of metastasis (time-to-recurrence [TTR]) of 15 months or longer (hazard ratio [HR] 0.23; p = 0.0063), no symptoms of recurrence (HR 0.23; p = 0.0126), and serum C-reactive protein (CRP) levels lower than than 0.5 mg/dl (HR 0.24; p = 0.0052) were significantly associated with better survival., Conclusions: Long-term survival could be achieved for some patients with mUC who underwent metastasectomy. Lung and lymph nodes were predominant sites for metastasectomy. Symptoms, TTR, and CRP value were identified as associated with survival and should be taken into account when metastasectomy is considered.
- Published
- 2017
- Full Text
- View/download PDF
188. NK cells activated by Interleukin-4 in cooperation with Interleukin-15 exhibit distinctive characteristics.
- Author
-
Kiniwa T, Enomoto Y, Terazawa N, Omi A, Miyata N, Ishiwata K, and Miyajima A
- Subjects
- Animals, CD11b Antigen genetics, CD11b Antigen immunology, Cell Proliferation, Gene Expression Regulation, Granulocyte-Macrophage Colony-Stimulating Factor genetics, Granulocyte-Macrophage Colony-Stimulating Factor immunology, Interferon-gamma genetics, Interferon-gamma immunology, Interleukin-10 genetics, Interleukin-10 immunology, Interleukin-15 genetics, Interleukin-15 pharmacology, Interleukin-4 genetics, Interleukin-4 pharmacology, Killer Cells, Natural drug effects, Killer Cells, Natural parasitology, Leukocyte Common Antigens genetics, Leukocyte Common Antigens immunology, Macrophages immunology, Macrophages parasitology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Nippostrongylus immunology, Nippostrongylus pathogenicity, Receptors, Interleukin-18 genetics, Receptors, Interleukin-18 immunology, Receptors, Interleukin-4 deficiency, Receptors, Interleukin-4 genetics, Receptors, Interleukin-4 immunology, Signal Transduction, Strongylida Infections genetics, Strongylida Infections parasitology, Cytotoxicity, Immunologic, Interleukin-15 immunology, Interleukin-4 immunology, Killer Cells, Natural immunology, Lymphocyte Activation, Strongylida Infections immunology
- Abstract
Natural killer (NK) cells are known to be activated by Th1-type cytokines, such as IL-2, -12, or -18, and they secrete a large amount of IFN-γ that accelerates Th1-type responses. However, the roles of NK cells in Th2-type responses have remained unclear. Because IL-4 acts as an initiator of Th2-type responses, we examined the characteristics of NK cells in mice overexpressing IL-4. In this study, we report that IL-4 overexpression induces distinctive characteristics of NK cells (B220(high)/CD11b(low)/IL-18Rα(low)), which are different from mature conventional NK (cNK) cells (B220(low)/CD11b(high)/IL-18Rα(high)). IL-4 overexpression induces proliferation of tissue-resident macrophages, which contributes to NK cell proliferation via production of IL-15. These IL-4-induced NK cells (IL4-NK cells) produce higher levels of IFN-γ, IL-10, and GM-CSF, and exhibit high cytotoxicity compared with cNK cells. Furthermore, incubation of cNK cells with IL-15 and IL-4 alters their phenotype to that similar to IL4-NK cells. Finally, parasitic infection, which typically causes strong Th2-type responses, induces the development of NK cells with characteristics similar to IL4-NK cells. These IL4-NK-like cells do not develop in IL-4Rα KO mice by parasitic infection. Collectively, these results suggest a novel role of IL-4 in immune responses through the induction of the unique NK cells., Competing Interests: The authors declare no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
189. Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD).
- Author
-
Kitamura T, Watanabe-Okochi N, Enomoto Y, Nakahara F, Oki T, Komeno Y, Kato N, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nishimura K, Hayashi Y, Nagase R, Saika M, Fukushima T, Asada S, Fujino T, Izawa Y, Horikawa S, Fukuyama T, Tanaka Y, Ono R, Goyama S, Nosaka T, Kitaura J, and Inoue D
- Subjects
- Animals, Cell Proliferation, Cell Transformation, Neoplastic genetics, Epigenesis, Genetic, Hematopoietic Stem Cells metabolism, Humans, Mice, Mice, Transgenic, Mutation, Oncogene Proteins, Fusion genetics, Phenotype, Carcinogenesis genetics, Hematologic Neoplasms genetics, Leukemia, Myeloid, Acute genetics, Myelodysplastic Syndromes genetics, Translocation, Genetic
- Abstract
Recent progress in high-speed sequencing technology has revealed that tumors harbor novel mutations in a variety of genes including those for molecules involved in epigenetics and splicing, some of which were not categorized to previously thought malignancy-related genes. However, despite thorough identification of mutations in solid tumors and hematological malignancies, how these mutations induce cell transformation still remains elusive. In addition, each tumor usually contains multiple mutations or sometimes consists of multiple clones, which makes functional analysis difficult. Fifteen years ago, it was proposed that combination of two types of mutations induce acute leukemia; Class I mutations induce cell growth or inhibit apoptosis while class II mutations block differentiation, co-operating in inducing acute leukemia. This notion has been proven using a variety of mouse models, however most of recently found mutations are not typical class I/II mutations. Although some novel mutations have been found to functionally work as class I or II mutation in leukemogenesis, the classical class I/II theory seems to be too simple to explain the whole story. We here overview the molecular basis of hematological malignancies based on clinical and experimental results, and propose a new working hypothesis for leukemogenesis., (© The Authors 2015. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
190. Mature resting Ly6C(high) natural killer cells can be reactivated by IL-15.
- Author
-
Omi A, Enomoto Y, Kiniwa T, Miyata N, and Miyajima A
- Subjects
- Animals, Granzymes immunology, Interferon Inducers pharmacology, Interleukin-15 pharmacology, Killer Cells, Natural, Mice, Poly I-C pharmacology, Antigens, Ly immunology, Cell Proliferation, Interferon-gamma immunology, Interleukin-15 immunology
- Abstract
Mature NK cells are heterogeneous as to their expression levels of cell surface molecules. However, the functional differences and physiological roles of each NK-cell subset are not fully understood. In this study, we report that based on the Ly6C expression levels, mature C57BL/6 murine NK cells can be subdivided into Ly6C(low) and Ly6C(high) subsets. Ly6C(high) NK cells are in an inert state as evidenced by the production of lower levels of IFN-γ and granzyme B, and they exhibit poorer proliferative potential than Ly6C(low) NK cells. In addition, adoptive transfer experiments revealed that Ly6C(high) NK cells are derived from Ly6C(low) NK cells in the steady state. These results strongly suggest that Ly6C(high) NK cells are resting cells in the steady state. However, in vitro, Ly6C(high) NK cells become Ly6C(low) NK cells with strong effector functions upon stimulation with IL-15. Moreover, Ly6C(high) NK cells also revert to Ly6C(low) NK cells in vivo upon injection of the IL-15 inducers polyI:C and CpG. Taken together, these results demonstrate the plasticity of mature NK cells and suggest that Ly6C(high) NK cells are a reservoir of potential NK cells that allow effective and strong response to infections., (© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2014
- Full Text
- View/download PDF
191. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
- Author
-
Koido S, Enomoto Y, Apostolopoulos V, and Gong J
- Subjects
- Adoptive Transfer, Animals, Antigen Presentation, Cell Fusion, Cytotoxicity, Immunologic, Humans, Mice, Mice, Inbred C57BL, CD4-Positive T-Lymphocytes immunology, Cancer Vaccines immunology, Dendritic Cells immunology, Mucin-1 immunology, Neoplasms, Experimental therapy
- Abstract
Background/aim: Vaccination with fusions of dendritic cells (DCs) and mucin-1 (MUC1)-positive tumor cells (FC/MUC1) induces MUC1-specific antitumor immunity. However, little is known about the function of Cluster of Differentiation (CD)4 T-cells primed with FC/MUC1 in MUC1 transgenic (MUC1.Tg) mice., Materials and Methods: CD4 T-cells primed with FC/MUC1 were analyzed by flow cytometry. Antitumor immunity by adoptive transfer of primed CD4 T-cells in Rag2(-/-) mice was assessed., Results: The effector and memory T-cells generated with FC/MUC1 were crucial to maintenance of long-term antitumor immunity. MUC1-8-mer peptide SAPDTRPA presented by FC/MUC1 was recognized by CD4 and CD8 T-cells. A subset of primed CD4 T-cells possessed cytotoxicity to lyse major histocompatibility complex (MHC) class I and MUC1 positive tumor cells. Interestingly, adoptive transfer of primed CD4 T-cells prevented lung metastasis in Rag2(-/-) mice., Conclusion: CD4 T-cells primed by FC/MUC1 play direct role in antitumor immunity., (Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2014
192. High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy.
- Author
-
Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H, Fukayama M, Yamaguchi H, Kakimi K, and Homma Y
- Abstract
Heat shock protein 105 (Hsp105) is one of the cancer/testis antigens, which is overexpressed in a variety of cancer cells, including urinary bladder cancer, and has been investigated as a target molecule for immunotherapy due to its immunogenicity. In this study, we assessed the expression of Hsp105 in primary bladder cancer samples from 84 patients treated with radical cystectomy, using immunohistochemical analysis, and investigated its correlation with clinicopathological characteristics and cancer-specific survival. The immunoreactivity of Hsp105 expression was evaluated as a score of 0-3, according to the intensity of the signal. The Hsp105 expression was high (score 2 or 3) in 31 cases and low (score 0 or 1) in 53 cases; however, it was not significantly correlated with age, nuclear grade, pathological tumor stage and previous intravesical Bacillus Calmette-Guérin immunotherapy. Female gender, lymphovascular invasion and lymph node metastasis were associated with low Hsp105 scores, although the differences were not statistically significant (P=0.071, 0.061 and 0.175, respectively). However, a high Hsp105 score was significantly associated with a favorable prognosis (P=0.017) and was identified as an independent prognostic factor by multivariate analysis (P=0.032; hazard ratio, 2.34). These findings suggested that the expression of Hsp105 may be a novel indicator of a favorable prognosis in bladder cancer.
- Published
- 2014
- Full Text
- View/download PDF
193. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
- Author
-
Yamada D, Nishimatsu H, Kumano S, Hirano Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Kume H, and Homma Y
- Subjects
- Adrenergic alpha-1 Receptor Antagonists pharmacology, Aged, Apoptosis drug effects, Cell Line, Tumor, HeLa Cells, Humans, Incidence, Male, Middle Aged, Multivariate Analysis, Naphthalenes pharmacology, Piperazines pharmacology, Proportional Hazards Models, Retrospective Studies, Risk Factors, Signal Transduction drug effects, Sulfonamides pharmacology, Sulfonamides therapeutic use, Tamsulosin, Transforming Growth Factor beta metabolism, Adrenergic alpha-1 Receptor Antagonists therapeutic use, Naphthalenes therapeutic use, Piperazines therapeutic use, Prostatic Neoplasms drug therapy, Prostatic Neoplasms epidemiology, Transforming Growth Factor beta antagonists & inhibitors
- Abstract
Objectives: Quinazoline-based α(1) -adrenoceptor antagonists are known to inhibit prostate tumor growth through induction of apoptosis. We investigated the effect of a naphthalene-based α(1) -adrenoceptor antagonist, naftopidil, on prostate cancer incidence, apoptosis of prostatic cell and transforming growth factor-β signaling., Methods: Prescription records were linked to pathological data for men who continued naftopidil (n = 766) or tamsulosin (n = 1015) for 3 months or longer between 2003 and 2010. Prostate cancer incidence was analyzed by log-rank test and the Cox proportional hazards model. Apoptosis and cell cycle arrest in human tissues were assessed by immunohistochemical detection of Bcl2 and p21, respectively. Growth inhibition and apoptosis treatment with naftopidil and tamsulosin were assessed in cancer cell lines. Interference with transforming growth factor-β signaling was examined by western blot analysis., Results: Prostate cancer incidence was significantly lower in men who received naftopidil for 3 months or longer compared with tamsulosin (P = 0.035). Multivariate analysis confirmed a decreased hazard ratio, 0.46, for naftopidil use (P = 0.013), which was more evident with longer treatment. Immunohistochemical positivity for Bcl2, a marker for resistance to apoptosis, was less frequently detected in prostate cancer cells of men who received naftopidil compared with tamsulosin (P < 0.05). Naftopidil inhibited cancer cell growth, induced apoptosis and blocked Smad2 phosphorylation activated by transforming growth factor-β in cell lines, with a half maximal inhibitory concentration of 1.1 µmol/L., Conclusions: Naftopidil seems to reduce prostate cancer incidence, possibly by inducing apoptosis, preferentially in cancer cells, and blocking transforming growth factor-β signaling., (© 2013 The Japanese Urological Association.)
- Published
- 2013
- Full Text
- View/download PDF
194. MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.
- Author
-
Enomoto Y, Kitaura J, Shimanuki M, Kato N, Nishimura K, Takahashi M, Nakakuma H, Kitamura T, and Sonoki T
- Subjects
- Animals, Bone Marrow Cells pathology, Bone Marrow Transplantation, Disease Progression, Gene Expression, Leukemia, Myeloid mortality, Leukemia, Myeloid pathology, Mice, Myeloid Cells pathology, Transduction, Genetic, CCAAT-Enhancer-Binding Protein-alpha genetics, Leukemia, Myeloid genetics, MicroRNAs genetics, Mutation
- Abstract
MicroRNA-125b-1 (miR-125b-1) is a target of the chromosomal translocations t(11;14)(q24;q32) and t(2;11)(p21;q23), which are found in human B-lymphoid and myeloid malignancies, respectively. These translocations result in overexpression of mature miR-125b, consisting of 22 nucleotides. To analyze the role of miR-125b-1 in leukemogenesis, we created a bone marrow transplantation model using a retrovirus vector containing GFP expression elements. Sole transduction of miR-125b-1 into bone marrow cells resulted in expansion of hematopoietic cells expressing GFP. Compared with cells lacking GFP expression, we observed that GFP(+)/CD11b(+) or GFP(+)/Gr(-)1(+) cells were increased in the bone marrow and spleen. Although previous studies reported sole induction of miR-125b-induced leukemia, we did not find leukemic transformation in our model. Transduction of miR-125b-1 did accelerate myeloid tumors induced by a C-terminal mutant of CAAT-enhancer binding protein (C/EBPα-C(m)), a class II-like mutation. As miR-125b has been shown to hasten the development of leukemia in a BCR/ABL-transduced animal model, our present results support the conclusion that overexpression of miR-125b cooperates with other genetic alterations in the pathogenesis of myeloid malignancies.
- Published
- 2012
- Full Text
- View/download PDF
195. [A case of renal carcinoid with local recurrence and multiple lymph node metastases 4 years after partial nephrectomy].
- Author
-
Komemushi Y, Nagata M, Nishimatsu H, Niimi A, Takazawa Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Ishikawa A, Kume H, Igawa Y, Fukayama M, and Homma Y
- Subjects
- Humans, Male, Middle Aged, Carcinoid Tumor pathology, Carcinoid Tumor surgery, Kidney Neoplasms pathology, Kidney Neoplasms surgery, Lymphatic Metastasis pathology, Neoplasm Recurrence, Local pathology, Nephrectomy
- Abstract
Primary renal carcinoid is an uncommon tumor. We report a case of local recurrence and multiple lymph node metastases of renal carcinoid 4 years after partial nephrectomy in a 64-year-old man. He was incidentally found to have a mass lesion in the right kidney and right partial nephrectomy was performed 4 years ago. Histological examination including immunohistochemical studies confirmed the diagnosis of the atypical primary renal carcinoid. After 4 years of follow up, abdominal ultrasonography and computed tomography demonstrated a local recurrence and multiple lymph node metastases around the inferior vena cava. He underwent right radical nephrectomy with paraaortic and right renal hilum lymphadenectomy. Histological appearance showed that recurrence of the atypical renal carcinoid. Four of the resected five lymph nodes were positive for metastasis. Unexpectedly, two tiny renal cell carcinomas were also found from the right kidney. The patient remains free from disease recurrence for 2 months post re-operation. This case is the 43rd report of renal carcinoid tumor in Japan.
- Published
- 2012
- Full Text
- View/download PDF
196. [Eight-year postsurgery recurrence of malignant fibrous histiocytoma of the left spermatic cord].
- Author
-
Kamei J, Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Igawa Y, and Homma Y
- Subjects
- Aged, Histiocytoma, Malignant Fibrous surgery, Humans, Male, Neoplasm Recurrence, Local, Genital Neoplasms, Male pathology, Histiocytoma, Malignant Fibrous pathology, Spermatic Cord
- Abstract
A 76-year-old man underwent high orchiectomy due to a painless tumor in the left inguinal region. Pathological diagnosis was malignant fibrous histiocytoma (MFH) of the left spermatic cord. Because of positive surgical margins, additional resection of the left scrotal wall and left inguinal canal combined with retroperitoneal lymphadenectomy were performed, with the surgical margins negative. Adjuvant therapy was not administered. Eight years later he noticed a painful subcutaneous mass in the left inguinal region. CT showed local recurrence and metastases of MFH to mesenteric lymph nodes and the left adrenal gland. The tumor grew rapidly and the patient died 1 month after admission. Autopsy revealed local recurrence of MFH and metastases of MFH to liver, lung, left adrenal gland, bone and lymph nodes. Recurrence of MFH with an interval of 8 years is a rare event.
- Published
- 2012
- Full Text
- View/download PDF
197. Docetaxel as a vital option for corticosteroid-refractory prostate cancer.
- Author
-
Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, and Homma Y
- Subjects
- Adenocarcinoma blood, Aged, Aged, 80 and over, Alkaline Phosphatase blood, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone administration & dosage, Dexamethasone therapeutic use, Docetaxel, Drug Resistance, Neoplasm, Humans, Karnofsky Performance Status, L-Lactate Dehydrogenase blood, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Proportional Hazards Models, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Retrospective Studies, Taxoids administration & dosage, Adenocarcinoma drug therapy, Adenocarcinoma pathology, Antineoplastic Agents therapeutic use, Prostatic Neoplasms drug therapy, Prostatic Neoplasms pathology, Taxoids therapeutic use
- Abstract
Objectives: The efficacy of docetaxel (TAX) chemotherapy for corticosteroid-refractory refractory prostate cancer (CRPC) is uncertain., Materials and Methods: We retrospectively reviewed outcomes of 51 men with corticosteroid-refractory CRPC treated at our institute. Of them, 24 men had received only dexamethasone (DEX) before the approval of TAX (historical control). The remaining 27 men who had already become DEX refractory on the approval of TAX underwent TAX plus DEX., Results: The median overall survival for men treated with TAX plus DEX (17.6 months) was significantly longer than men with DEX (8.1 months, P = 0.021). On univariate analysis, performance status, lactate dehydrogenase (LDH), alkaline phosphatase (ALP), prostate specific antigen (PSA), and TAX therapy were significant factors for overall survival. Of these, performance status and TAX therapy remained as the significant factor on multivariate analysis. No significant benefit was detected for men with advanced disease such as poorer performance status, elevated LDH, elevated ALP, or high PSA. Grades 3, 4 toxicities including anemia (19%), leukocytopenia (26%), and neutropenia (26%) were found in TAX cases., Conclusions: Our results suggest that TAX would be a vital option for DEX refractory CRPC possibly with more efficacy for less advanced stages.
- Published
- 2011
- Full Text
- View/download PDF
198. Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population.
- Author
-
Suzuki M, Liu M, Kurosaki T, Suzuki M, Arai T, Sawabe M, Kasuya Y, Kato M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Kume H, Homma Y, and Kitamura T
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma therapy, Aged, Aged, 80 and over, Genetic Association Studies, Genotype, Humans, Japan, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Prostatic Neoplasms mortality, Prostatic Neoplasms therapy, Adenocarcinoma genetics, Chromosomes, Human, Pair 8 genetics, Polymorphism, Single Nucleotide, Prostatic Neoplasms genetics
- Abstract
Unlabelled: We conducted present study to address whether the rs6983561 polymorphism, an established genetic marker for prostate cancer susceptibility, was a prognostic indicator. We genotyped 518 Japanese patients with prostate cancer and analysed their survival retrospectively. As a result, patients with the CA/CC genotype of rs6983561 survived significantly longer than those with the AA genotype (P = .033)., Background: Genome-wide association studies have revealed several genetic variants at 8q24 that are associated with prostate cancer susceptibility. Rs6983561 (A/C) is a single-nucleotide polymorphism located at 8q24 that has been established as a genetic risk marker for prostate cancer susceptibility. The present study investigated the association between the rs6983561 polymorphism and prostate cancer mortality in a Japanese population., Patients and Methods: The study examined 518 native Japanese male patients with sporadic prostate cancer. Germline DNA samples were obtained from all participants and genotyping of rs6983561 was performed using a TaqMan assay. Observation periods were from the date of diagnosis of prostate cancer to May 21, 2010. The Cox proportional hazards model was used to estimate the cause-specific survival (CSS) and the overall survival (OS)., Results: Patients with the CA/CC genotype of rs6983561 survived significantly longer than those with the AA genotype. In a multivariate model, the hazard ratios (HRs) and 95% confidence intervals (CIs) of the CSS and the OS for the rs6983561 polymorphism were 2.438 (1.262 - 5.046, P = .007) and 1.957 (1.142 - 3.485, P = .014), respectively. When the analysis was restricted to subjects with metastatic disease, the HRs of the CSS and the OS were 3.353 (95% CI, 1.689 - 7.446; P = 3.76 x 10(-4)) and 3.361 (95% CI, 1.741 - 7.136; P = 1.70 x 10(-4)), respectively., Conclusion: In the Japanese population examined in this study, the rs6983561 polymorphism at 8q24 was significantly associated with prostate cancer mortality, especially among patients with metastatic disease., (Copyright © 2011. Published by Elsevier Inc.)
- Published
- 2011
- Full Text
- View/download PDF
199. Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling.
- Author
-
Endo Y, Suzuki M, Yamada H, Horita S, Kunimi M, Yamazaki O, Shirai A, Nakamura M, Iso-O N, Li Y, Hara M, Tsukamoto K, Moriyama N, Kudo A, Kawakami H, Yamauchi T, Kubota N, Kadowaki T, Kume H, Enomoto Y, Homma Y, Seki G, and Fujita T
- Subjects
- Adipocytes cytology, Adipocytes drug effects, Adipocytes metabolism, Animals, Blotting, Western, Cation Transport Proteins metabolism, Cell Differentiation drug effects, Cells, Cultured, Embryo, Mammalian cytology, Embryo, Mammalian drug effects, Embryo, Mammalian metabolism, ErbB Receptors metabolism, Extracellular Signal-Regulated MAP Kinases metabolism, Fibroblasts cytology, Fibroblasts drug effects, Fibroblasts metabolism, Humans, Immunoenzyme Techniques, Immunoprecipitation, Kidney Tubules, Proximal cytology, Mice, Mice, Inbred C57BL, PPAR gamma genetics, Phosphorylation drug effects, Rabbits, Rats, Rats, Wistar, Sodium-Hydrogen Exchanger 1, Sodium-Hydrogen Exchangers metabolism, Species Specificity, src-Family Kinases metabolism, Bicarbonates metabolism, Kidney Tubules, Proximal drug effects, Kidney Tubules, Proximal metabolism, PPAR gamma metabolism, Signal Transduction drug effects, Sodium metabolism, Thiazolidinediones pharmacology
- Abstract
Thiazolidinediones (TZDs) improve insulin resistance by activating a nuclear hormone receptor, peroxisome proliferator-activated receptor γ (PPARγ). However, the use of TZDs is associated with plasma volume expansion through a mechanism that remains to be clarified. Here we showed that TZDs rapidly stimulate sodium-coupled bicarbonate absorption from the renal proximal tubule in vitro and in vivo. TZD-induced transport stimulation is dependent on PPARγ-Src-EGFR-ERK and observed in rat, rabbit and human, but not in mouse proximal tubules where Src-EGFR is constitutively activated. The existence of PPARγ-Src-dependent nongenomic signaling, which requires the ligand-binding ability, but not the transcriptional activity of PPARγ, is confirmed in mouse embryonic fibroblast cells. The enhancement of the association between PPARγ and Src by TZDs supports an indispensable role of Src in this signaling. These results suggest that the PPARγ-dependent nongenomic stimulation of renal proximal transport is also involved in TZD-induced volume expansion., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
200. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors?
- Author
-
Kume H, Kakutani S, Yamada Y, Shinohara M, Tominaga T, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, and Homma Y
- Subjects
- Humans, Male, Middle Aged, Prognosis, Proportional Hazards Models, Retrospective Studies, Risk Factors, Survival Rate, Bone Neoplasms secondary, Carcinoma, Renal Cell secondary, Kidney Neoplasms pathology, Survivors
- Abstract
Purpose: Renal cell carcinoma is sometimes associated with bone metastasis. Several risk factors have been reported but some are still controversial. Also, the significance of laboratory tests has not been fully examined for such cases., Materials and Methods: We collected data on 94 renal cell carcinoma cases with bone metastasis treated at 3 tertiary referral centers. Clinicopathological parameters and outcome data were analyzed to search for predictors of overall survival retrospectively. The log rank test and the Cox proportional hazard model were used for univariate and multivariate analyses, respectively., Results: There were 64 males with a median age of 63.9 years. Histological diagnosis showed clear cell renal cell carcinoma in 63 patients, nonclear cell renal cell carcinoma in 7 and unclassified cancer in 6. Sarcomatoid differentiation was found in 17 cases. Metastasis was detected synchronously in 37 patients or metachronously at a median interval of 33.1 months. Multivariate analysis identified sarcomatoid differentiation (p = 0.001), vertebral bone involvement (p = 0.003), extraosseous metastasis (p = 0.021), alkaline phosphatase increased to 1.5 times the upper limit of normal (p = 0.0003) and C-reactive protein increased to greater than 0.3 mg/dl (p = 0.018) as significant risk factors. Cases were classified into 3 groups based on the number of risk factors, including low risk-28 with 0 or 1 risk factor, intermediate risk-26 with 2 risk factors and high risk-40 with 3 to 5 risk factors. This grouping clearly separated survival among these groups (each p <0.001). It also confirmed the usefulness of the Memorial-Sloan Kettering Cancer Center classification system., Conclusions: Our risk classification incorporating 5 risk factors enables accurate prediction of survival, which can be helpful to make clinical decisions in cases of renal cell carcinoma with bone metastasis., (Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.